Clinical Trial

Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated April 1, 2026 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase I/II open-label, efficacy and safety study of bicalutamide in combination with sunitinib in patients with advanced renal cell carcinoma (RCC) who have been treated with a receptor tyrosine kinase inhibitor (RTKI) and experienced disease progression.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-01-18; most recent amendment 2026-03-26.
Status change: Not Yet Recruiting → Recruiting 2025-02-13
Trial Details
NCT Number NCT06222593
Lead Sponsor State University of New York at Buffalo
Conditions Carcinoma, Renal Cell
Enrollment 28 participants
Start Date 2024-10-01
Primary Completion 2026-07-01 (estimated)
Study Completion 2027-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-01